Mot de passe
Afficher le mot de passe
Mot de passe oublié ?
Devenir membre gratuitement
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Cotations dynamiques 


SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur HYBRIGENICS SA
08/09Bone Therapeutics ziet resultaten licht verbeteren
07/09BONE THERAPEUTICS : reacts to the press release issued by Hybrigenics
07/09Brussel blijft in het rood
07/09Brussel licht omlaag
07/09Brussel iets lager van start
07/09CORRECTIE : Vlakke start Bel20 voorzien
07/09Vlakke start Bel20 voorzien
07/09BONE THERAPEUTICS : to Evaluate Potential Merger Talks With Hybrigenics
07/09Hybrigenics zoekt opnieuw toenadering tot Bone Therapeutic
06/09Hybrigenics zoekt opnieuw toenadering tot Bone Therapeutics
17/05Hybrigenics Société Anonyme agreed to acquire a 46.64% stake in Inoviem Scientific SAS ..
06/05Hybrigenics Société Anonyme announced that it has received funding
03/05SPAC, ROBINHOOD, BITCOIN, INFLACIÓN : ¿qué piensa Warren Buffett?
03/05EN DIRECTO DESDE LOS MERCADOS : Credit Suisse, Tesla, Apple, DBV, Carbios, Verizon, Siemen..
22/03América acelera, Europa se estanca
2019Biotechnology Division of Diagnostic Medical Systems S.A. completed the acquisition of ..
2019Biotechnology Division of Diagnostic Medical Systems S.A. agreed to acquire Hybrigenics..
2018Management acquired Helixio from Hybrigenics Société Anonyme.
2017Hybrigenics Société Anonyme Reports Consolidated Earnings Results for the Half Year End..
2017HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) and shows act..
2017HYBRIGENICS : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 2017
2017HYBRIGENICS : gets European patent protection for inhibitors of Ubiquitin-Specific Proteas..
2017HYBRIGENICS : full year 2016 results
2017Hybrigenics SA Announces Consolidated Earnings Results for the Full Year Ended December..
2017HYBRIGENICS : Strategic refocusing on biopharmaceutical R&D
2017HYBRIGENICS : Encouraging preliminary results of the Phase II clinical study of inecalcito..
2017Hybrigenics Provides Update on Phase II Clinical Study of inecalcitol in Chronic Myeloi..
2017HYBRIGENICS' : patent estate of inhibitors of ubiquitin specific proteases continues to ex..
2016Hybrigenics SA Announces Consolidated Earnings Results for the First Half Year Ended Ju..
2016HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the United States un..
2016HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase II clinical..
2014HYBRIGENICS : 2014 first-half results and highlights
2014HYBRIGENICS : successfully raised € 4.6 million
2014HYBRIGENICS : invests in its genomic capabilities
2014HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is expanding
2014HYBRIGENICS : revenus et trésorerie au premier semestre 2014
2013HYBRIGENICS : Hybrigenics' General Meeting highlights - Focus on inecalcitol recent update..
2013HYBRIGENICS : Update on the clinical study of inecalcitol in chronic lymphocytic leukemia
2013HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging brain
2013HYBRIGENICS : Hybrigenics' Technology Platform Successfully Applied to the Study of Rare G..
2013HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in chronic lym..
2013HYBRIGENICS : launches a new service to screen interactions between small molecules and pr..
2012HYBRIGENICS : green ligt for two European patents protecting new oral formulations of inec..
2012HYBRIGENICS : launches a new website
2012HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same level as ..
2012HYBRIGENICS : Hybrigenics' General Meeting Highlights
2012HYBRIGENICS : Bryan, Garnier & Co initiates coverage of Hybrigenics with a target price of..
2012HYBRIGENICS : Bryan Garnier initiates coverage of Hybrigenics with a target price of € 2.6
2012HYBRIGENICS : completed its private placement to institutional investors up to EUR 3.3 mil..
2012HYBRIGENICS : gets approval and financing for a phase II clinical trial of oral inecalcito..
Prochain événement sur HYBRIGENICS SA